The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Open accessAbstract
Germline aberrations in critical DNA-repair and DNA damage–response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality can be exploited in such malignancies, as exemplified by approval of poly(ADP-ribose) polymerase inhibitors for treating BRCA1/2-mutated ovarian cancers. Herein, we detail how cellular DDR processes engage various proteins that sense DNA damage, initiate signaling pathways to promote cell-cycle checkpoint activation, trigger apoptosis, and coordinate DNA repair. We focus on novel therapeutic strategies targeting promising DDR targets and discuss challenges of patient selection and the development of rational drug combinations. Significance: Various inhibitors of DDR components are in preclinical and clinical development. A thorough understanding of DDR pathway complexities must now be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clinical success. Cancer Discov; 7(1); 20–37. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationThe DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Self-citationDNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., & Bonner, W. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5858 · Cited by 5,438 · cited 4×
“ATM is the principal kinase responsible for the phosphorylation of histone H2AX on serine 139 (known as γH2AX) (50), although some functional”
BackgroundInfluentialSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Shiloh, Y., & Ziv, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3546 · Cited by 1,649 · cited 3×
“ATM is also important for the stabilization of p53 through the phosphorylation and subsequent inhibition of proteosomal degradation by MDM2 (54).”
BackgroundInfluentialDNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
Repair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex
Lee, J.-H., & Paull, T. T. (2005) · Science · doi:10.1126/science.1108297 · Cited by 1,424
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
The multifaceted mismatch-repair system
Jiricny, J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1907 · Cited by 1,370
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage
Falck, J., Coates, J., & Jackson, S. P. (2005) · Nature · doi:10.1038/nature03442 · Cited by 1,258
Self-citationLord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“For example, the silencing of the BRCA1 gene through promoter hypermethylation has been demonstrated in breast and ovarian cancers (149), which highlights the importance of also considering functional biomarker assays, rather than relying on genomics in isolation.”
BackgroundHickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Self-citationStucki, M., Clapperton, J. A., Mohammad, D., Yaffe, M. B., Smerdon, S. J., & Jackson, S. P. (2005) · Cell · doi:10.1016/j.cell.2005.09.038 · Cited by 1,099
Self-citationGaillard, H., García-Muse, T., & Aguilera, A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3916 · Cited by 1,089
DNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationBouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3185 · Cited by 947
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
Blunt, T., Finnie, N. J., Taccioli, G. E., Smith, G. C. M., Demengeot, J., Gottlieb, T. M., Mizuta, R., Varghese, A. J., Alt, F. W., Jeggo, P. A., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90360-7 · Cited by 864
Self-citationHelleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 856
Mechanisms underlying mutational signatures in human cancers
Helleday, T., Eshtad, S., & Nik-Zainal, S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3729 · Cited by 838
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Mateos-Gomez, P. A., Gong, F., Nair, N., Miller, K. M., Lazzerini-Denchi, E., & Sfeir, A. (2015) · Nature · doi:10.1038/nature14157 · Cited by 765
GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase
Jackson, S. P., MacDonald, J. J., Lees-Miller, S., & Tjian, R. (1990) · Cell · doi:10.1016/0092-8674(90)90296-q · Cited by 669
Self-citationUse of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
THE GENETIC DEFECT IN ATAXIA-TELANGIECTASIA
Lavin, M. F., & Shiloh, Y. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.177 · Cited by 643
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 1×
“Beyond PARP inhibitors, preclinical data have demonstrated synergy between ATR inhibition and impaired ATM signaling, particularly in the context of exogenous DNA damage (119).”
BackgroundHuman HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
Miller, K. M., Tjeertes, J. V., Coates, J., Legube, G., Polo, S. E., Britton, S., & Jackson, S. P. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1899 · Cited by 629
Self-citationRegulation of DNA Damage Responses by Ubiquitin and SUMO
Jackson, S. P., & Durocher, D. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.017 · Cited by 601
Self-citationIbrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
Gad, H., Koolmeister, T., Jemth, A.-S., Eshtad, S., Jacques, S. A., Ström, C. E., Svensson, L. M., Schultz, N., Lundbäck, T., Einarsdottir, B. O., et al. (2014) · Nature · doi:10.1038/nature13181 · Cited by 514
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
Flynn, R. L., Cox, K. E., Jeitany, M., Wakimoto, H., Bryll, A. R., Ganem, N. J., Bersani, F., Pineda, J. R., Suvà, M. L., Benes, C. H., et al. (2015) · Science · doi:10.1126/science.1257216 · Cited by 506
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
Fousteri, M., & Mullenders, L. H. (2008) · Cell Research · doi:10.1038/cr.2008.6 · Cited by 487
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
DNA double strand break repair via non-homologous end-joining.
Davis, A. J., & Chen, D. J. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.04.02 · Cited by 456
Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage
Deriano, L., & Roth, D. B. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155540 · Cited by 453
Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441
Zhao, Y., Thomas, H. D., Batey, M. A., Cowell, I. G., Richardson, C. J., Griffin, R. J., Calvert, A. H., Newell, D. R., Smith, G. C. M., & Curtin, N. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4275 · Cited by 445
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442
Predictors of Competing Mortality in Advanced Head and Neck Cancer
Mell, L. K., Dignam, J. J., Salama, J. K., Cohen, E. E. W., Polite, B. N., Dandekar, V., Bhate, A. D., Witt, M. E., Haraf, D. J., Mittal, B. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9288 · Cited by 433
Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., Kalva, S., Potter, J., Tran, T. V., Chen, J., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0475-x · Cited by 419
Manke, I. A., Nguyen, A., Lim, D., Stewart, M. Q., Elia, A. E. H., & Yaffe, M. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.021 · Cited by 416
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Huber, K. V. M., Salah, E., Radic, B., Gridling, M., Elkins, J. M., Stukalov, A., Jemth, A.-S., Göktürk, C., Sanjiv, K., Strömberg, K., et al. (2014) · Nature · doi:10.1038/nature13194 · Cited by 395
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 373
Translational Control in Cancer Etiology
Ruggero, D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012336 · Cited by 367
Mammalian Base Excision Repair: the Forgotten Archangel
Dianov, G. L., & Hübscher, U. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt076 · Cited by 363
Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells
Bindra, R. S., Schaffer, P. J., Meng, A., Woo, J., Måseide, K., Roth, M. E., Lizardi, P., Hedley, D. W., Bristow, R. G., & Glazer, P. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8504-8518.2004 · Cited by 356
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
An ATR- and Cdc7-Dependent DNA Damage Checkpoint that Inhibits Initiation of DNA Replication
Costanzo, V., Shechter, D., Lupardus, P. J., Cimprich, K. A., Gottesman, M., & Gautier, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00799-2 · Cited by 353
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs
Bindra, R. S., Gibson, S. L., Meng, A., Westermark, U., Jasin, M., Pierce, A. J., Bristow, R. G., Classon, M. K., & Glazer, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2119 · Cited by 334
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327
PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair
Ochi, T., Blackford, A. N., Coates, J., Jhujh, S., Mehmood, S., Tamura, N., Travers, J., Wu, Q., Draviam, V. M., Robinson, C. V., et al. (2015) · Science · doi:10.1126/science.1261971 · Cited by 322
Self-citationDo, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Buisson, R., Boisvert, J. L., Benes, C. H., & Zou, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.029 · Cited by 316 · cited 3×
“ATR appears particularly important for the suppression of replication catastrophe in early S-phase cells through the promotion of ribonucleotide reductase accumulation and by limiting origin firing (59).”
BackgroundInfluentialRNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair
Galanty, Y., Belotserkovskaya, R., Coates, J., & Jackson, S. P. (2012) · Genes & Development · doi:10.1101/gad.188284.112 · Cited by 314
Self-citationBang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2251 · Cited by 288
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 285
Jette, N., & Lees-Miller, S. P. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.12.003 · Cited by 282
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Self-citationHistone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
Wee1 kinase as a target for cancer therapy
Do, K., Doroshow, J. H., & Kummar, S. (2013) · Cell Cycle · doi:10.4161/cc.26062 · Cited by 273
Leijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 264
Beyond DNA Repair: DNA-PK Function in Cancer
Goodwin, J. F., & Knudsen, K. E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0358 · Cited by 258 · cited 1×
“Interestingly, DNA-PK has also long been known to have links to transcription (42), and studies are currently ongoing to investigate the mechanisms by which transcriptional regulation by DNA-PK affects DNA repair (43).”
BackgroundYap, T. A., O’Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J., Tunariu, N., Perez-Lopez, R., Rodrigues, D. N., Riisnaes, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02404 · Cited by 251
Self-citationBeyond DNA Repair: Additional Functions of PARP-1 in Cancer
Weaver, A. N., & Yang, E. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00290 · Cited by 246
Stracker, T. H., Usui, T., & Petrini, J. H. J. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.04.012 · Cited by 243
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 243
An exonucleolytic activity of human apurinic/apyrimidinic endonuclease on 3′ mispaired DNA
Chou, K.-M., & Cheng, Y.-C. (2002) · Nature · doi:10.1038/415655a · Cited by 239 · cited 1×
“In addition, APE1 harbors exonuclease activity important for the removal of 3′ obstructive lesions in DNA, including chain-terminating nucleoside analogues (87).”
BackgroundPoly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Self-citationAnticancer therapy with checkpoint inhibitors: what, where and when?
Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 202
Pal, A., Young, M. A., & Donato, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1211 · Cited by 199
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Targeting ATR in DNA damage response and cancer therapeutics
Fokas, E., Prevo, R., Hammond, E. M., Brunner, T. B., McKenna, W. G., & Muschel, R. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.002 · Cited by 189
Daud, A. I., Ashworth, M. T., Strosberg, J., Goldman, J. W., Mendelson, D., Springett, G., Venook, A. P., Loechner, S., Rosen, L. S., Shanahan, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5027 · Cited by 185
DNA single-strand break repair
Caldecott, K. W. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.027 · Cited by 178
Ubiquitylation, neddylation and the DNA damage response
Brown, J. S., & Jackson, S. P. (2015) · Open Biology · doi:10.1098/rsob.150018 · Cited by 177
Self-citationPreclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., Hirsch, H. A., Feldman, I., Benita, Y., Toniatti, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0025 · Cited by 172
Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase
Beck, H., Nähse, V., Larsen, M. S. Y., Groth, P., Clancy, T., Lees, M., Jørgensen, M., Helleday, T., Syljuåsen, R. G., & Sørensen, C. S. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200905059 · Cited by 169
Alternative end-joining pathway(s): Bricolage at DNA breaks
Frit, P., Barboule, N., Yuan, Y., Gomez, D., & Calsou, P. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.02.007 · Cited by 167
Sarantopoulos, J., Shapiro, G. I., Cohen, R. B., Clark, J. W., Kauh, J. S., Weiss, G. J., Cleary, J. M., Mahalingam, D., Pickard, M. D., Faessel, H. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1338 · Cited by 167
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
Hong, D., Infante, J., Janku, F., Jones, S., Nguyen, L. M., Burris, H. A., Naing, A., Bauer, T. M., Piha-Paul, S., Johnson, F. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5788 · Cited by 159
DNA damage and innate immunity: links and trade-offs
Chatzinikolaou, G., Karakasilioti, I., & Garinis, G. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.06.003 · Cited by 158
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 158
Neddylation Promotes Ubiquitylation and Release of Ku from DNA-Damage Sites
Brown, J. S., Lukashchuk, N., Sczaniecka-Clift, M., Britton, S., le Sage, C., Calsou, P., Beli, P., Galanty, Y., & Jackson, S. P. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.058 · Cited by 152
Self-citationPolycomb repressive complex 2 contributes to DNA double-strand break repair
Campbell, S., Ismail, I. H., Young, L. C., Poirier, G. G., & Hendzel, M. J. (2013) · Cell Cycle · doi:10.4161/cc.25795 · Cited by 150
HERC2 Is an E3 Ligase That Targets BRCA1 for Degradation
Wu, W., Sato, K., Koike, A., Nishikawa, H., Koizumi, H., Venkitaraman, A. R., & Ohta, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1304 · Cited by 150
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
Sanjiv, K., Hagenkort, A., Calderón‐Montaño, J. M., Koolmeister, T., Reaper, P. M., Mortusewicz, O., Jacques, S. A., Kuiper, R., Schultz, N., Scobie, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.032 · Cited by 149
PARP inhibitors: the race is on
Brown, J. S., Kaye, S. B., & Yap, T. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.67 · Cited by 149
Self-citationATM and ATR Signaling Regulate the Recruitment of Human Telomerase to Telomeres
Tong, A. S., Stern, J. L., Sfeir, A. J., Kartawinata, M., de Lange, T., Zhu, X., & Bryan, T. M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.041 · Cited by 139
Lim, J. Y., Yang, K. Y., Taylor‐Harding, B., Wiedemeyer, W. R., & Buckanovich, R. J. (2014) · Neoplasia · doi:10.1016/j.neo.2014.04.003 · Cited by 136
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
Dietlein, F., Kalb, B., Jokić, M., Noll, E. M., Strong, A., Tharun, L., Ozretić, L., Künstlinger, H., Kambartel, K.-O., Randerath, W. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.053 · Cited by 129
A new approach to the study of the base-excision repair pathway using methoxyamine.
Liuzzi, M., & Talpaert-Borlè, M. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89014-7 · Cited by 125
Karp, J. E., Thomas, B. M., Greer, J. M., Sorge, C. L., Gore, S. D., Pratz, K. W., Smith, B. D., Flatten, K. S., Peterson, K., Schneider, P. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2442 · Cited by 123
Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells
Murakawa, Y., Sonoda, E., Barber, L. J., Zeng, W., Yokomori, K., Kimurâ, H., Niimi, A., Lehmann, A. R., Zhao, G., Hochegger, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1166 · Cited by 119
How cancer cells hijack DNA double-strand break repair pathways to gain genomic instability
Jeggo, P. A., & Löbrich, M. (2015) · Biochemical Journal · doi:10.1042/bj20150582 · Cited by 113
Competition, collaboration and coordination – determining how cells bypass DNA damage
Sale, J. E. (2012) · Journal of Cell Science · doi:10.1242/jcs.094748 · Cited by 109
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy
Kelderman, S., Schumacher, T. N., & Kvistborg, P. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.012 · Cited by 104
One ring to bring them all—The role of Ku in mammalian non-homologous end joining
Grundy, G. J., Moulding, H., Caldecott, K. W., & Rulten, S. L. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.02.019 · Cited by 103
Deubiquitylating Enzymes and DNA Damage Response Pathways
Jacq, X., Kemp, M. I., Martin, N. M. B., & Jackson, S. P. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9635-3 · Cited by 99
Self-citationDouble strand break (DSB) repair in heterochromatin and heterochromatin proteins in DSB repair
Boumendil, C., & Soutoglou, E. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.03.015 · Cited by 95
Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells
Fathers, C., Drayton, R. M., Solovieva, S. E., & Bryant, H. E. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19482 · Cited by 94
McNeish, I. A., Oza, A. M., Coleman, R. L., Scott, C. L., Konecny, G. E., Tinker, A. V., O’Malley, D. M., Brenton, J. D., Kristeleit, R. S., Bell‐McGuinn, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5508 · Cited by 93
Jackson, S. P., & Helleday, T. (2016) · Science · doi:10.1126/science.aab0958 · Cited by 83
Self-citationSchmutz, I., & de Lange, T. (2016) · Current Biology · doi:10.1016/j.cub.2016.01.056 · Cited by 82
New directions in poly(ADP‐ribose) polymerase biology
Bock, F. J., & Chang, P. (2016) · FEBS Journal · doi:10.1111/febs.13737 · Cited by 80
Disassembly of MDC1 Foci Is Controlled by Ubiquitin-Proteasome-dependent Degradation
Shi, W., Ma, Z., Willers, H., Akhtar, K., Scott, S. P., Zhang, J., Powell, S. N., & Zhang, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801082200 · Cited by 76
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Thijssen, R., ter Burg, J., Garrick, B., van Bochove, G. G. W., Brown, J. R., Fernandes, S. M., Rodriguez, M. S., Michot, J., Hallek, M. J., Eichhorst, B. F., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700328 · Cited by 75
Self-citationMortensen, D. S., Perrin-Ninkovic, S. M., Shevlin, G. I., Elsner, J., Zhao, J., Whitefield, B., Tehrani, L. R., Sapienza, J., Riggs, J. R., Parnes, J. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00627 · Cited by 75
Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents
Kee, Y., Huang, M., Chang, S. C., Moreau, L. A., Park, E., Smith, P. G., & D’Andrea, A. D. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0497 · Cited by 68
Matthews, T. P., Jones, A. M., & Collins, I. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.788496 · Cited by 67
Linking DNA Damage and Hormone Signaling Pathways in Cancer
Schiewer, M. J., & Knudsen, K. E. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.02.004 · Cited by 66
Dent, R. A., Lindeman, G. J., Clemons, M. J., Wildiers, H. P. M. W., Chan, A., McCarthy, N. J., Singer, C., Lowe, E. S., Kemsley, K., & Carmichael, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1018 · Cited by 63
Ubiquitin and SUMO in DNA repair at a glance
Ulrich, H. D. (2012) · Journal of Cell Science · doi:10.1242/jcs.091801 · Cited by 63
Calvo, E., Chen, V. J., Marshall, M. S., Ohnmacht, U., Hynes, S. M., Kumm, E., Diaz, H. B., Barnard, D., Merzoug, F. F., Huber, L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0114-5 · Cited by 63
WEE1 Kinase As a Target for Cancer Therapy
Mueller, S., & Haas-Kogan, D. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.2290 · Cited by 53
Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
Grabocka, E., Commisso, C., & Bar‐Sagi, D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0650 · Cited by 53
Garcia, K., Blank, J. L., Bouck, D. C., Liu, X. J., Sappal, D. S., Hather, G., Cosmopoulos, K., Thomas, M. P., Kuranda, M., Pickard, M. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0634 · Cited by 52
Blasius, M., Wagner, S., Choudhary, C., Bártek, J., & Jackson, S. P. (2014) · Genes & Development · doi:10.1101/gad.246272.114 · Cited by 51
Self-citationScott, D. E., Coyne, A. G., Venkitaraman, A. R., Blundell, T. L., Abell, C., & Hyvönen, M. (2014) · ChemMedChem · doi:10.1002/cmdc.201402428 · Cited by 42
Agarwal, P., & Jackson, S. P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.009 · Cited by 41
Self-citationChera, B. S., Sheth, S. H., Patel, S. A., et al. (2021) · Cancer · doi:10.1002/cncr.33789 · Cited by 40
Murray, L., Cooper, J. A., Hughes, C. M., Powe, D. G., & Cardwell, C. R. (2014) · Breast Cancer Research · doi:10.1186/bcr3638 · Cited by 39
Doi, T., Yoshino, T., Shitara, K., Matsubara, N., Fuse, N., Naito, Y., Uenaka, K., Nakamura, T., Hynes, S. M., & Bence, A. K. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000278 · Cited by 37
Gordon, M. S., Rosen, L. S., Mendelson, D. S., Ramanathan, R. K., Goldman, J., Liu, L., Xu, Y., Gerson, S. L., Anthony, S. P., Figg, W. D., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9876-9 · Cited by 37
Matulonis, U. A., Wulf, G. M., Birrer, M. J., Westin, S. N., Quy, P., Bell‐McGuinn, K. M., Lasonde, B., Whalen, C., Aghajanian, C. A., Solit, D. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2510 · Cited by 36
Oza, A. M., Weberpals, J. I., Provencher, D. M., Grischke, E., Hall, M., Uyar, D. S., Estevez-Diz, M. D. P., Marmé, F., Kuzmin, A., Rosenberg, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5506 · Cited by 35
O’Carrigan, B., Miguel, M. J. D., Papadatos-Pastos, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2504 · Cited by 35
Self-citationPlummer, E. R., Dean, E. J., Evans, T. R. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2513 · Cited by 31
Münster, P. N., Mahipal, A., Nemunaitis, J. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2505 · Cited by 21
Karachaliou, N., Costa, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Mayo, C., Massutí, B., Majem, M., Carcereny, E., Morán, T., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db621 · Cited by 19
Yap, T. A., Miguel, M. J. D., O’Carrigan, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-pr14 · Cited by 18
Self-citationMichalarea, V., Roda, D., Drew, Y., Carreira, S., O’Carrigan, B., Shaw, H. M., Roux, R. L., Kumar, S. S., Ward, S. E., Parmar, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct010 · Cited by 14
Self-citationShapiro, G. I., Wesolowski, R., Middleton, M. R., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct012 · Cited by 12
Bauer, T. M., Jones, S. F., Greenlees, C., Cook, C., Jewsbury, P. J., Mugundu, G. M., French, T., Pierce, A. J., O’Connor, M. J., Laing, N. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps2608 · Cited by 11
Meehan, R. S., Chen, A. P., Coyne, G. O., Collins, J. M., Kummar, S., Anderson, L. D., Jr., Ishii, K., Zlott, J., Rubinstein, L., Horneffer, Y. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2556 · Cited by 6
Chera, B. S., Gupta, G. P., Weiss, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps6106 · Cited by 6
Cited by
ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961
Self-citationState-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Self-citationGenomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
Metadata
- Authors
- Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A.
- Venue
- Cancer Discovery
- Published
- 2017-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 20-37
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2562712448
- Cited by
- 618
- References
- 163
- FWCI
- 24.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.